Cancer
Showing of 74 results
University Hospitals Seidman Cancer Center Researchers Find Age Should Be a Consideration in Metastatic Prostate Cancer Treatment Plans
The study, published in the October 28, 2025 edition of New England Journal of Medicine Evidence, was led by senior author Daniel Spratt, MD.
Randomized Clinical Trial Led by University Hospitals Seidman Cancer Center Oncologist Leads to Practice-Changing Precision Prostate Cancer Therapy
Randomized trial validates first biomarker tool to guide hormone treatment decisions, allowing for more personalized prostate cancer care.
University Hospitals Seidman Cancer Center Named Catalyst Awards Finalist for Excellence in Quality Performance and Measures
Recognized for innovative work improving data integration and enhancing the accuracy and efficiency of tumor registry processes.
Kathy Coleman Commits Additional $3.5 Million to Fuel the Future of Clinical Trials at University Hospitals Seidman Cancer Center
UH plans to triple clinical trials capacity by 2030.
Pilot Study Provides Foundation for Understanding How Music Therapy Improves Pain After Pancreatic Surgery
A new study from University Hospitals Connor Whole Health found that it was feasible to conduct a live music-assisted relaxation and imagery session among patients admitted for pancreatic surgery.
Case Comprehensive Cancer Center receives $25.5M grant renewal to continue work in cancer treatment, prevention, and therapeutic innovation
The renewal marks 38 years of continuous NCI funding, dating back to the organization’s founding in 1987.
Team of Researchers, including University Hospitals Co–Senior Author, Finds not all Low-Grade Prostate Cancers are Low Risk
The study, published July 31 in the journal JAMA Oncology, found that one in six men with GG1 category cancer turns out to have intermediate- or high-risk cancer when other clinical features are considered in addition to biopsy results.
David’s Warriors St. Baldrick’s Research Grant Awarded to UH Rainbow Physician Researcher for Pediatric Neuroblastoma Study
The grant will support Dr. John Letterio’s project titled, “Development of a Novel NF-κB Targeting Agent for Pediatric Neuroblastoma” focused on improving treatment outcomes for children with high-risk neuroblastoma.